Hua Medicine
Hua Medicine, officially known as Hua Medicine (Shanghai) Co., Ltd., is a pioneering biopharmaceutical company headquartered in Shanghai, China. Founded in 2016, the company focuses on the development of innovative therapies for diabetes and related metabolic disorders, positioning itself at the forefront of the healthcare industry. With a commitment to advancing diabetes treatment, Hua Medicine has developed unique products, including its lead candidate, HM15136, which aims to improve glycaemic control. The company has achieved significant milestones, including successful clinical trials that underscore its potential to transform diabetes management. Recognised for its cutting-edge research and development capabilities, Hua Medicine is rapidly establishing itself as a key player in the global biopharmaceutical market, dedicated to enhancing patient outcomes through innovative solutions.
DitchCarbon Score
How does Hua Medicine's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Hua Medicine's score of 2 is lower than 61% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Hua Medicine's reported carbon emissions
In 2023, Hua Medicine reported total carbon emissions of approximately 435,747 kg CO2e, comprising about 19,201 kg CO2e from Scope 1 and about 416,546 kg CO2e from Scope 2 emissions. This represents a slight increase in emissions compared to 2022, where total emissions were about 329,500 kg CO2e, with Scope 1 at approximately 17,170 kg CO2e and Scope 2 at about 312,330 kg CO2e. In 2021, the company recorded total emissions of about 482,280 kg CO2e, with Scope 1 emissions at approximately 15,190 kg CO2e and Scope 2 emissions at about 413,090 kg CO2e. Despite these figures, Hua Medicine has not disclosed any specific reduction targets or initiatives aimed at decreasing their carbon footprint. The absence of climate pledges or commitments suggests a need for further action in addressing their environmental impact. As the company continues to grow, it will be crucial for them to establish clear climate commitments to align with industry standards and expectations.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 15,190 | 00,000 | 00,000 |
| Scope 2 | 413,090 | 000,000 | 000,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Hua Medicine is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
